Now the ballots have been cast at the general election, the UK could become the 'reassuringly boring' market, both politically and fiscally, when compared to the more extreme politics on the other side of the English Channel and Atlantic Ocean.So suggests Jean Roche, manager of the Schroder UK Mid Cap Fund (SCP), who notes capital allocators know more or less what to expect, which could explain th

AstraZeneca's cancer drug combo gets green lightApplications being reviewed in several countriesCovid-19 prevention drug gets fast-trackedA combination of AstraZeneca's (AZN) cancer treatments Imfinzi and Lynparza has been recommended for approval in the EU by the CHMP (Committee for Medicinal Products for Human Use) for patients with certain advanced or recurrent endometrial cancer.In addition, I

US approval for endometrial cancer drugLeads to 58% improvement in survival ratesImfinzi generated sales of $4.2 billionPharmaceutical giant AstraZeneca (AZN) said it has received US regulatory approval for its cancer drug Imfinzi to treat patients with advanced or recurrent endometrial cancer.The approval was based on results from a late-stage trial which showed Imfinzi plus carboplatin and pacli

Annual sales plunge 18%Cost-cutting drives improved H2 performanceNew CEO sets out recovery and growth strategyMind Gym's (MIND:AIM) shares slumped the best part of 30% to an all-time low of 27.5p after the corporate training specialist reported an 18% plunge in sales for the year to 31 March 2024 driven by constricted customer HR (human resources) budgets and warned the new financial year will be

European equities closed lower on Monday, with markets unnerved by election results in Europe, ahead of a US interest rate decision later in the week.The FTSE 100 index closed down 16.89 points, 0.2%, at 8,228.48. The FTSE 250 ended down 109.33 points, 0.5%, at 20,446.04, and the AIM All-Share fell 5.25 points, 0.7%, at 788.28.The Cboe UK 100 ended down 0.3% at 820.02, the Cboe UK 250 also fell 0.

Court rules 70,000 plaintiffs can present evidenceGSK to seek appealBlood cancer drug receives positive resultsShares in GSK (GSK) fell 10% to the bottom of the FTSE 100 after a Delaware judge on Friday (31 May) allowed more than 70,000 Zantac cases, which claim the discontinued heartburn drug caused cancer, to proceed to trial.French pharmaceutical firm Sanofi (SAN:EPA), which is also embroiled i

Move strengthens US footprintAdds over 40,000 academic titlesBloomsbury shares gain on dealPublishing house Bloomsbury (BMY) announced this morning it had agreed to buy academic publisher Rowman & Littlefield for £65 million.Bloomsbury is financing the acquisition from its own cash resources and a new £30 million three-year term loan with Lloyds Bank (LLOY).The acquisition marks another step tow

Equities in London ended lower on Tuesday after the long weekend, with investors nervy ahead of a US inflation reading on Friday, with comments from a Federal Reserve central banker doing little to lift spirits.The UK election campaign rumbled on as all three of the main party leaders spent Tuesday visiting seats that could be crucial in deciding the outcome of the general election.Prime Minister

First Zantac trial winSecond case dismissedShares continue to recoverGSK (GSK) has won the first legal case to be heard in the ongoing Zantac litigation cases after a Chicago jury ruled in its favour and dismissed the plaintiff's claim that the drug had caused her colorectal cancer.Angela Valadez has taken Zantac and generic versions of the drug between 1995 and 2014 and was seeking $640 million i

Copper is already one of the most important materials underpinning human civilisation, and the energy transition is only likely to see demand for the industrial metal build in the years to come.Limits and pressures on supply and this growing demand profile are already seeing copper prices mount a charge and recent M&A activity ? with BHP's (BHP) unsuccessful (for now) attempt to take over Anglo Am

Kainos (KNOS) £10.16Market cap: £1.28 billionWe believe that market sentiment towards Kainos (KNOS) is on the cusp of a reversal, and that creates a buying opportunity for investors. Shares in the Belfast-based digital services expert are now trading at a 30% discount to 12-month highs and are barely half all-time peaks of more than £20.This is largely because of what analysts have called a cyc

Stocks in London started strong on Friday following the Bank of England?s dovish hold on interest rates on Thursday, as new data showed UK gross domestic product reached a stronger-than-expected level in March.The FTSE 100 index opened up 43.05 points, 0.5%, at 8,424.40. The FTSE 250 was up 68.41 points, 0.3%, at 20,599.71, and the AIM All-Share was up 2.06 points, 0.3%, at 785.76.The Cboe UK 100

Third quarter sales up 5.2%Full year profit seen top endUpgrades to earnings estimatesThe post-pandemic recovery at JD Wetherspoon (JDW) continues at pace after the pub group delivered another period of strong like-for-like sales growth and said full-year profit was expected to come in at the top end of market expectations.The news sent the shares 3% higher to 748.6p, meaning they are roughly flat

Stock prices in London opened higher on Wednesday, beating Asian peers which trended lower over night, and following a flatter session in the US.The FTSE 100 index opened up 34.20 points, 0.4%, at 8,347.87. The FTSE 250 was up 30.83 points, 0.2%, at 20,443.91, and the AIM All-Share was up 1.94 points, 0.3%, at 778.36.The Cboe UK 100 was up 0.4% at 833.39, the Cboe UK 250 was up 0.3% at 17,713.33,

Stocks prices in London were higher at midday on Tuesday, as local data added to the uplift provided by US markets on Monday.The FTSE 100 index was up 82.73 points, 1.0%, at 8,296.22. The FTSE 250 was up 225.42 points, 1.1%, at 20,389.96, and the AIM All-Share was 5.72 points, 0.7%, at 777.25.The Cboe UK 100 was up 1.0% at 828.39, the Cboe UK 250 was up 1.0% at 17,662.42, and the Cboe Small Compan

Stocks in London were in the green on Tuesday morning, tracking a rise in global equities following weaker US jobs data and a UK public holiday on Monday.The FTSE 100 index opened up 69.25 points, 0.8%, at 8,282.95. The FTSE 250 was up 187.86 points, 0.9%, at 20,352.21, and the AIM All-Share was up 4.81 points, 0.6%, at 776.37.The Cboe UK 100 was up 0.9% at 826.93, the Cboe UK 250 was up 0.9% at 1

Just when investors think they have got the measure of Tesla (TSLA:NASDAQ), Elon Musk drops a bomb. Having feared the worst, Tesla?s first quarter (Q1) 2024 report (25 April) gave investors the clarity they were seeking on mass-market vehicles, and while detail remains thin, Musk said production would likely begin ?in early 2025, if not later this year? and would include ?more affordable models.?T

Interest rates are expected to stay higher for longer to combat the sticky inflation which remains a threat to investors? hard-earned wealth and purchasing power. During periods of high inflation, it is crucial to invest in companies that possess pricing power, because these firms can pass on increased costs to customers, enabling them to maintain profit margins and generate the robust cash flows

Gaming Realms (GMR:AIM) 31.6pMarket cap: £93.4 millionFor the uninitiated, Gaming Realms (GMR:AIM) is a leading business-to-business licensor and distributor of games to the regulated gaming market.The company owns the IP (intellectual property) to the Slingo brand, one of the most popular formats of games played online.As the name suggests the format is a mash-up of slots and bingo. The game in

Stocks in London ended in the red on Wednesday, despite the FTSE 100 hitting another record high earlier in the day, while Tesla was the star in New York, where wider markets mixed.The FTSE 100 index gave back 4.43 points, 0.1%, at 8,040.38. The blue-chip index traded as high as 8,092.19 earlier Wednesday, its best-ever level. Selling pressure in the afternoon prevented it from achieving another c